
    
      Trial design This multicenter, randomized, controlled trial is conducted by the French
      Myeloma Intergroup(IFM) in elderly patients with previously untreated multiple myeloma. The
      primary objectives of the study are to compare the efficacy and safety of MP with
      MP-Thalidomide or with MEL100 (intermediate-dose melphalan 100 mg/m2 - based treatment). The
      secondary objective is to compare the efficacy of MP-Thalidomide vs MEL100.
    
  